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gastrointestinal surgery (DREAMS)
Emma Hamilton1*, Reena Ravikumar2, David Bartlett3, Elizabeth Hepburn4, Mei-Ju Hwang1, Nazzia Mirza5,
Sandeep S Bahia6, Anthony Wilkey7, Helen Bodenham Chilton8, Kelly Handley8, Laura Magill8, Dion Morton9
and on behalf of the West Midlands Research CollaborativeAbstract
Background: Postoperative nausea and vomiting is one of the most common complications affecting patients after
surgery and causes significant morbidity and increased length of hospital stay. It is accepted that patients
undergoing surgery on the bowel are at a higher risk. In the current era of minimally invasive colorectal surgery
combined with enhanced recovery, reducing the incidence and severity of postoperative nausea and vomiting is
particularly important. Dexamethasone is widely, but not universally used. It is known to improve appetite and
gastric emptying, thus reduce vomiting. However, this benefit is not established in patients undergoing bowel
surgery, and dexamethasone has possible side effects such as increased risk of wound infection and anastomotic
leak that could adversely affect recovery.
Design: DREAMS is a phase III, double-blind, multicenter, randomized controlled trial with the primary objective of
determining if preoperative dexamethasone reduces postoperative nausea and vomiting in patients undergoing
elective gastrointestinal resections. DREAMS aims to randomize 1,350 patients over 2.5 years.
Patients undergoing laparoscopic or open colorectal resections for malignant or benign pathology are randomized
between 8 mg intravenous dexamethasone and control (no dexamethasone). All patients are given one additional
antiemetic at the time of induction, prior to randomization. Both the patient and their surgeon are blinded as to
the treatment arm.
Secondary objectives of the DREAMS trial are to determine whether there are other measurable benefits during
recovery from surgery with the use of dexamethasone, including quicker return to oral diet and reduced length of
stay. Health-related quality of life, fatigue and risks of infections will be investigated.
Trial registration: ISRCTN21973627
Keywords: Anti-emetics, Colorectal surgery, Dexamethasone, Enhanced recovery, Gastrointestinal/surgery,
Post-operative nausea and vomitingBackground
Postoperative nausea and vomiting (PONV) is one of the
most common complications affecting patients after sur-
gery. The pathophysiology of PONV is multifactorial, but
as patients undergoing colorectal surgery are exposed to
various causative agents in addition to the physical factors
of bowel manipulation predisposing to ileus, they are at
a substantially higher risk of this problem. Following* Correspondence: emmamowatt@gmail.com
1West Midlands Deanery/West Midlands Research Collaborative, Birmingham,
UK
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© 2013 Hamilton et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orsurgical intervention, patients view PONV as a very un-
desirable outcome, even more unpleasant than pain [1]. It
causes significant morbidity, delays nutrition and increases
the length of stay in hospital. Given that over 60,000 colo-
rectal operations are performed annually in the UK alone,
PONV has significant medical and cost implications to
healthcare.Pathophysiology of PONV
The pathophysiology of nausea and vomiting is complex.
The vomiting centre in the medulla receives stimulation
from various sources, including the chemoreceptor triggeral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and the cerebral cortex. The multifactorial mechanisms
underlying PONV include stimulation of dopamine and 5-
hydroxytryptamine type 3 receptors in the chemoreceptor
trigger zone by noxious substances such as opiates and an-
aesthetic agents, and the stimulation of gut chemorecep-
tors and stretch receptors. Despite advances in antiemetic
agents, anaesthetic agents and minimally invasive surgical
techniques, PONV remains a significant and persistent
problem. Other risk factors that increase the likelihood of
PONV are female gender, non-smoking status, history of
motion sickness, childhood and young adulthood, and in-
creasing length of surgery [2]. Intra-abdominal and laparo-
scopic surgery has been implicated as having an increased
risk of PONV. A comparison of predictive models for
PONV [3] found that intra-abdominal surgery had an
odds ratio of 1.23 (n = 217) but this included patients who
underwent gynecological laparoscopy. Laparoscopic chole-
cystectomy had an odds ratio of 2.85 (n = 42).
Clinical relevance of PONV
After surgery, the overall incidence of PONV is 30%,
and it is up to 70% in high-risk patients [2]. In a study
investigating the 10 most undesirable postoperative
outcomes, vomiting ranked first, gagging on the endo-
tracheal tube second, and postoperative pain third [1].
Nausea was ranked fourth. Although mortality rates are
rarely affected, PONV can cause significant morbidity
including dehydration, electrolyte disturbance, delayed
return to diet and aspiration pneumonia. Delayed re-
covery in the hospital setting predisposes to serious
and life-threatening complications such as hospital-
acquired pneumonia and thromboembolic events (deep
venous thrombosis and pulmonary embolism). The
delay in patients resuming an oral diet affects nutrition
and subsequent general well-being, predisposing to tis-
sue breakdown, pressure sores, wound infection, fa-
tigue, weakness and delay in mobilization.
In the current era of minimally invasive colorectal sur-
gery combined with enhanced recovery protocols to
optimize recovery and reduce the length of patient hos-
pital stay, reducing the incidence and severity of PONV is
particularly important. The cost implications related to
prolonged hospital stay and the additional costs of further
complications affect both open and laparoscopic surgery.
Dexamethasone for PONV
Dexamethasone is extensively used in all types of surgery
to reduce PONV (Table 1). In practice, dexamethasone
is less widely used for control of PONV by anesthetists
in gastrointestinal patients, perhaps because of a lack of
proven efficacy in these patients. However, its use is ad-
vocated in some enhanced recovery programs (ERAS) to
improve recovery after colorectal surgery [4-6].Its precise mechanism of action is unknown but it has
been proposed that the antiemetic properties arise due to
activation of glucocorticoid receptors in the medulla [25],
or by inhibiting central production of prostaglandins or
inhibiting the release of endogenous opioids [26]. It is also
known to improve appetite [27], and in combination with
reduced nausea and vomiting, aids early recovery. Gluco-
corticoids can also reduce pain by suppression of bradyki-
nin and neuropeptides from nerve endings [26].
Dexamethasone does have potential theoretical side ef-
fects such as increased risks of wound infections and
anastomotic leaks that could adversely affect recovery,
but a systematic review of 51 studies using a single dose
of methylprednisolone in cardiac, general and trauma
surgical patients found no significant increase in adverse
events [28].
Dexamethasone use in abdominal surgery
In 2008, a systematic review and meta-analysis of 17
randomized clinical trials looking at preoperative dexa-
methasone in patients undergoing laparoscopic chole-
cystectomy was published [29]. This review suggested
that, regardless of co-intervention (the administration of
other antiemetics in the control arm), dexamethasone
reduced the incidence of nausea and vomiting. Small
studies investigating use of dexamethasone to reduce
PONV in many other fields of surgery have been under-
taken (Table 1). However, there are only two single cen-
ter colorectal trials, totaling 100 patients, that have
assessed this guidance in patients undergoing gastro-
intestinal surgery [9,10]. Interestingly, one of these trials
[9] measured cytokine levels in peritoneal drain fluid
following colorectal surgery and found significantly
reduced levels of IL-6, a pro-inflammatory cytokine
produced by T-cells and macrophages. There was a sig-
nificant reduction in IL-13 (a cytokine involved in type 2
T-helper cell responses), which is a stimulator of inflam-
mation and tissue remodeling at sites of T-helper type 2
inflammation. There was also a reduction in plasma
levels of IL-6 and IL-8, another major stimulator of the
inflammatory response. These changes in cytokine levels
correlated with improved fatigue scores.
The well-conducted Apfel et al. study from 2004 ran-
domized over 4,000 patients and assessed 64 different
combinations of anesthetic measures [7]. They concluded
that dexamethasone was effective in preventing PONV.
However, only 11% of patients in this study underwent
general surgical procedures and only a small fraction of
these underwent major colorectal surgery. Patients under-
going colorectal surgery comprise an especially high-risk
population for PONV, and may gain considerable benefit
from dexamethasone. As yet, there is little evidence to
support its use in colorectal surgery and a prospective
multicenter trial is required.
Table 1 Literature review of use of dexamethasone for PONV
Author Year n Type of surgery Findings Reference
Apfel et al. 2004 5,199 Gynecological, Trauma, Abdominal, Otolaryngology Ondansetron, dexamethasone, and droperidol each reduced the risk of PONV by 26% [7]
Wallenborn et al. 2006 3,140 Gynecological, Trauma Abdominal, Otolaryngology Metoclopramide plus dexamethasone is an effective, safe and cheap way to prevent PONV [8]
Zagar-Shostari et al. 2009 60 Colorectal Dexamethasone in an enhanced recovery protocol gives a significant reduction in early
postoperative fatigue, and an attenuated peritoneal cytokine response
[9]
Kirdak et al. 2008 30 Colorectal Dexamethasone has no significant effect on reducing postoperative pain, inflammatory
response or PONV
[10]
Weren and Demeere 2008 118 Abdominal and Gynecological Steroids are mostly effective in the prevention of late PONV (rather than early). [11]
Hans et al. 2006 32 Abdominal After dexamethasone, blood glucose levels increase in both patients without
diabetes and those with type 2 diabetes undergoing abdominal surgery. In
patients without diabetes blood sugar levels rose to a maximum of 10 mmol / litre
[12]
Coloma et al. 2001 80 Anorectal Reduction in time to ‘home readiness’ in ambulatory surgery [13]
Gautam et al. 2008 150 Laparoscopic cholecystectomy Combination of ondansetron and dexamethasone is better than each drug alone [14]
Tiippana et al. 2008 160 Laparoscopic cholecystectomy Dexamethasone decreased the need for opiates [15]
Bianchin et al. 2007 80 Laparoscopic cholecystectomy Reduced PONV. No change in pain or time to discharge. [16]
Wang et al. 1999 90 Laparoscopic cholecystectomy Dexamethasone significantly decreased the incidence of PONV [17]
Sanchez- Rodriguez et al. 2010 210 Laparoscopic cholecystectomy Dexamethasone significantly reduced PONV at 0, 6, 12 hours and reduced postoperative
pain and fatigue
[18]
Mathiesen et al. 2009 116 Gynecological Reduced PONV. Combinations of paracetamol, pregabalin and dexamethasone
did not reduce morphine consumption.
[19]
Biswas et al. 2003 160 Gynecological Ondansetron plus dexamethasone is most effective in preventing PONV. Results
comparable for single agents.
[20]
Yursek et al. 2003 60 Gynecological Ondansetron, but not dexamethasone, prevented PONV by 3 h post operation [21]
Wang et al. 2000 90 Gynecological Dexamethasone significantly decreases the incidence of PONV [22]
McKean et al. 2006 72 Otolaryngology Significant decrease in PONV and pain scores [23]
Mathew et al. 2004 210 Pediatrics Dexamethasone is effective for the prevention of PONV after strabismus repair in children [24]
PONV:postoperative nausea and vomiting.
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anesthetic used had no effect on the incidence of nausea
and vomiting. The additional antiemetic given at induc-
tion will not be standardized in the proposed trial. This
will maximize the generalizability of the findings.
The need for DREAMS – a large, multicenter,
randomized trial
Randomized controlled trials have shown a reduction in
PONV among patients undergoing various other types of
surgery who are given dexamethasone. In the absence of
good evidence, dexamethasone is variably used in patients
undergoing colorectal surgery. We have surveyed six major
colorectal units in the West Midlands region and found
that 25% of colorectal patients currently receive dexa-
methasone. The Dexamethasone Reduces Emesis After
Major Gastrointestinal Surgery (DREAMS) trial seeks to
determine the effectiveness of dexamethasone for colorectal
patients. No adequately powered multicenter trial has been
undertaken to conclusively assess the effect of dexametha-
sone on PONV in patients undergoing bowel surgery. The
aim of DREAMS is to evaluate the potential benefits of a
single dose of dexamethasone at induction for patients
undergoing colorectal surgery. The findings from DREAMS
may also give an indication of its appropriate use inside and
outside of ERAS, although this would require further con-
firmatory research.Methods
Trial design
The DREAMS trial is a two stage trial, comprising a pilot
study followed by a large, phase III double-blind, multi-
center, randomized controlled trial comparing the effects
of a single dose of 8 mg intravenous dexamethasone on
patient recovery after major gastrointestinal surgery. Cen-
ters in the UK undertaking major elective gastrointestinal
surgery will be eligible to take part.
Ethical approval
Full ethical approval has been gained from the East
Midlands Research Ethics Committee (ref: 10/H0402/77).
Randomized comparison
Patients undergoing laparoscopic or open gastrointestinal
resections will be randomized, in a 1:1 ratio, between 8 mg
intravenous dexamethasone and control. All patients must
be given one additional antiemetic prior to randomization;
however, this must not be dexamethasone.
Inclusion criteria
All patients undergoing elective open and laparoscopic
small and large bowel operations for malignant or benign
pathology will be eligible for inclusion. This includes smalland large bowel resections, defunctioning stomas and clo-
sures of stomas.
Exclusion criteria
The exclusion criteria are:
 diabetes or hyperglycemia
 active gastric ulceration confirmed endoscopically
 acute angle glaucoma
 bowel obstruction
 pregnancy
 under 18 years of age
 patients currently taking any form of steroid
medication, or have taken steroids in the last 3
months (except steroidal inhalers, suppositories,
pessaries, eye-drops, one-off local injections to a
joint and topical preparations)
 a known adverse reaction to dexamethasone
 patients taking immunosuppressive agents
including, but not limited to, methotrexate and
antiretrovirals.
On admission, patients will have blood glucose levels
checked to exclude undiagnosed hyperglycemia. Patients
unable or unwilling to give written informed consent for
the study are also excluded.
Primary outcome measure
The primary objective of the main phase of DREAMS
will be to determine whether preoperative dexametha-
sone reduces PONV within the first 24 hours in patients
undergoing elective gastrointestinal resections. The pri-
mary outcome measure will be the number of episodes
of vomiting within 24 hours post-surgery, recorded pro-
spectively on trial care charts.
Secondary outcome measure
Comparisons will be made to assess the effect of dexa-
methasone on the following outcomes:
 nausea and vomiting measured objectively by the
frequency of use of ‘as required’ postoperative
antiemetics
 nausea measured subjectively by the validated
PONV Intensity Scale
 fatigue measured using a validated assessment score
(Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F) questionnaire)
 time to tolerating oral diet
 length of hospital stay
 health-related quality of life (as measured by the
EuroQol EQ-5D)
 incremental cost-effectiveness of dexamethasone
compared to standard care
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days of surgery.
Infections and complications specifically assessed in-
clude wound infections, dehiscence, anastomotic leaks,
intra-abdominal collections, urinary or chest infections,
and new onset diabetes.
Randomization
Secure internet-based central randomization is available 24
hours a day and will ensure concealment of treatment allo-
cation. Each center and each randomizer will be provided
with a unique log-in and password to enable them to ac-
cess the online randomization service. Participants will be
randomized into the DREAMS trial, in a 1:1 ratio, to 8 mg
intravenous dexamethasone or to control (no dexametha-
sone). A ‘minimization’ procedure using a computer-based
algorithm will be used to avoid chance imbalances in im-
portant stratification variables. The stratification variables
are gender, smoking status, American Society of Anesthesi-
ologists (ASA) score, open and laparoscopic surgical cases,
intended postoperative analgesia (intravenous patient-
controlled analgesia (PCA), epidural infusion or epidural
PCA), and patients within and outside of an ERAS path-
way. For trial purposes, ERAS is defined as any recovery
process that is expedient over traditional patient care to in-
clude but not exclusive to earlier feeding and mobilization.
The definition of ERAS is specifically left broad to
recognize the differences in implementation of this sys-
tem across the various units.
Power calculation
The DREAMS trial aims to recruit a total of 1,350 patients
from around 30 colorectal units. With 1,350 patients ran-
domized, DREAMS would have 90% power to detect a 24%
proportional reduction (37% to 28%) in episodes of PONV
in patients taking dexamethasone after undergoing gastro-
intestinal surgery. This number includes an additional 10%
for crossover and dropout. Subgroup analyses will be
undertaken for variables for which the randomization is
stratified (for example, enhanced versus non-enhanced re-
covery pathway, PCA versus epidural) using standard tests
for interactions. Additional exploratory analyses will also be
undertaken to investigate, for example, any correlation be-
tween operative length and risk of nausea and vomiting.
Analysis of the study will be on an intention-to-treat basis.
Feasibility study
A lead-in phase II feasibility study was undertaken be-
fore the full phase III trial; it was planned that these pa-
tients would be included in the phase III trial analysis.
The aim of the pilot study was to inform the processes
to be used in the main trial. Three main areas were
addressed: the strategies used for the identification ofeligible patients; defining the patient pathway; and evalu-
ation of the case report forms. In addition to this, the
process of blinding in theater required development.
Two forms of treatment allocation were evaluated in the
feasibility study, by telephone and by email. Randomization
was done online (detailed below). But it was found that
email treatment allocation was difficult to quality control
because of the large number of anesthetists supporting the
trial. After the first 100 patients, telephone randomization
was used, as this allowed the trial team to check the patient
was anesthetized before the allocation was released, thus
reducing a potential source of bias.
The patient pathway and ability of centers to recruit
was assessed because DREAMS requires support from
both surgeons and anesthetists to maximize recruitment
and to ensure that all eligible patients are approached.
Recruitment was assessed on a monthly basis. The initial
aim was that by the end of the pilot study (measured as
six months after the study opened to recruitment), one
patient per center per week should be recruited from
five open centers. Within DREAMS, potential patients
can be identified from a number of clinical settings; in
the pilot, the percentage of eligible patients screened for
entry into the trial was recorded and the subsequent ac-
ceptance rate was a measure of the success of the
process for patient identification and randomization.
Across all sites there will be variations in the patient
pathway as the logistics and timings of patients being
seen in the outpatient clinic, pre-admissions and admis-
sions will differ from trust to trust. As part of the feasi-
bility study, the patient pathway was assessed through
the patient retention rate at the end of the pilot.
The ability of the investigators to collect the data re-
quired for the case report forms was also assessed within
the pilot trial; the end-points are both objective and sub-
jective, requiring input from clinicians, patients and
from trial care charts filled in by nursing staff. Through-
out the trial, the successful completion and return rates
of the case report forms will be measured and the return
rate of all case report forms should be over 70%.Patient pathway
Patients will be seen by a member of the trial team (the
Principle Investigator, Research Investigator or a Colo-
rectal Nurse Specialist), who will discuss the trial with
the patients and give them the ‘Patient Information
Sheet’ and consent forms (Figure 1).
Patients will have the opportunity to further discuss
the study at their preoperative assessment or on their
day of admission with the Principal Investigator or
Research Investigator at each hospital. The Principal
Investigator or Research Investigator will obtain written
informed consent.
Patient identified
Receive Patient Information Sheet (PIS) 
Check blood glucose (before obtain consent)
DREAMS TRIAL 
PROCESSES
DREAMS PATIENT 
JOURNEY
Outpatient appointment
Pre op clinic
Admission
Anaesthetic
Operation
Day 1 & 3 post-op
Day 5 post-op (or 
discharge)
Day 30 post-op
Obtain consent (if benign pathology)
Obtain consent (benign or malignant 
pathology) and inform trials unit 
Baseline QoL forms (EuroQoL EQ-5D and 
FACIT-F QoL)
Separate research investigator (with no 
other involvement in trial) to contact trials 
unit for randomisation 
Dexamethasone
8mg IV 
No dexamethasone 
Intraoperative form 
Nausea and vomiting proforma
Nausea and vomiting proforma 
QoL forms (EuroQoL EQ-5D and FACIT-F 
QoL)
Patient completed review (by telephone)
QoL forms (EuroQoL EQ-5D and FACIT-F 
QoL)
Figure 1 Trial design and patient journey. IV, intravenous; QoL, quality of life.
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trial, patients should be asked to complete the EuroQoL
EQ-5D Quality of Life Questionnaire and the FACIT-F
fatigue questionnaire.
All patients will be submitted to general anesthesia.
This is not standardized in the trial. The randomized
allocation will only be given to the anesthetist (or their
operating department practitioner), following induction
and after the administration of the one other antiemetic
of the anesthetist’s choice. This is to maintain the
double-blinding in the trial and to avoid bias in the
anesthetic regimen.
Following surgery, patients will be given antiemetics as
required. The choice of antiemetic will be as per local
policy. Twenty-four hours post-operation, dexametha-
sone can be prescribed for the patient; however this
must be on an ‘as required’ basis only. Dexamethasone
must not be prescribed to a patient within the first 24
hours post-operation.Follow-up data will include a nausea and vomiting re-
view completed postoperatively at days 1, 3 and 5 (or
day of discharge). This will include episodes of nausea
and vomiting captured from patients’ care charts and
antiemetic use captured from drug charts. Patients will
also be requested to complete the validated Post
Operative Nausea and Vomiting Intensity Scale at these
time-points. Quality of life forms, including the FACIT-F
Fatigue questionnaire, should be completed prior to sur-
gery and then at 5 and 30 days postoperatively. An assess-
ment of wound and chest infection as well as other
complications during the postoperative period will be
done via an outpatient appointment or telephone call 30
days postoperatively.Trial status
At the time of submission this trial is open to recruit-
ment in 36 centers and has recruited 719 patients.
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